Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | DNA gyrase subunit A | 0.0371 | 0.039 | 0.0254 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0956 | 0.2019 | 1 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.033 | 0.0276 | 0.073 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0956 | 0.2019 | 0.1906 |
Trypanosoma brucei | DNA topoisomerase ii | 0.2205 | 0.5496 | 1 |
Schistosoma mansoni | prokaryotic DNA topoisomerase | 0.0281 | 0.0139 | 0.0689 |
Loa Loa (eye worm) | hypothetical protein | 0.0637 | 0.113 | 0.5274 |
Schistosoma mansoni | lipoxygenase | 0.033 | 0.0276 | 0.1369 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.3823 | 1 | 1 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0956 | 0.2019 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0956 | 0.2019 | 1 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0956 | 0.2019 | 0.358 |
Plasmodium falciparum | DNA gyrase subunit A | 0.0371 | 0.039 | 0.0254 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.033 | 0.0276 | 0.073 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0956 | 0.2019 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0637 | 0.113 | 0.5274 |
Plasmodium vivax | DNA gyrase subunit A, putative | 0.0371 | 0.039 | 0.0254 |
Plasmodium falciparum | DNA gyrase subunit B | 0.3823 | 1 | 1 |
Mycobacterium ulcerans | DNA gyrase subunit A | 0.0371 | 0.039 | 0.0254 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.3823 | 1 | 1 |
Leishmania major | DNA topoisomerase ii | 0.0675 | 0.1237 | 0.205 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.3823 | 1 | 1 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.3823 | 1 | 1 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.3823 | 1 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.2205 | 0.5496 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0833 | 0.1676 | 1 |
Chlamydia trachomatis | DNA gyrase subunit A | 0.0371 | 0.039 | 0.0254 |
Schistosoma mansoni | DNA topoisomerase II | 0.0956 | 0.2019 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0956 | 0.2019 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.2205 | 0.5496 | 1 |
Mycobacterium leprae | Probable DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) | 0.1249 | 0.2835 | 1 |
Brugia malayi | Probable DNA topoisomerase II | 0.0956 | 0.2019 | 1 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0956 | 0.2019 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.2574 | 0.6523 | 0.6474 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.0956 | 0.2019 | 1 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0675 | 0.1237 | 0.205 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0956 | 0.2019 | 1 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0675 | 0.1237 | 0.205 |
Schistosoma mansoni | prokaryotic DNA topoisomerase | 0.0281 | 0.0139 | 0.0689 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.2166 | 0.5389 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0675 | 0.1237 | 0.205 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0675 | 0.1237 | 0.205 |
Treponema pallidum | DNA gyrase, subunit A (gyrA) | 0.0371 | 0.039 | 0.0254 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0956 | 0.2019 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0956 | 0.2019 | 1 |
Toxoplasma gondii | DNA gyrase/topoisomerase IV, A subunit domain-containing protein | 0.0371 | 0.039 | 0.0478 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0956 | 0.2019 | 0.1906 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.2205 | 0.5496 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.